In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Pharmaceutical Co. Ltd.

www.takeda.com

Latest From Takeda Pharmaceutical Co. Ltd.

Finance Watch: Moderna Launches Biggest Biopharma IPO Ever As US Market Resets Expectations

Public Company Edition: Moderna's $604m IPO launches as the US stock market is in decline and public biotechs are doing especially poorly. Also, as Shire acquisition closing moves near, Takeda firms up additional financing; and Global Blood, Theravance, Amarin capitalize on good news.

Financing Business Strategies

Actelion Is Third Company To Settle Charity Co-Pay Kickback Claims With DOJ

Company agrees to pay $360m to resolve allegations it used a charity as a conduit to pay Medicare patient copays for its drugs; several other companies are under investigation.

Policy Enforcement

Mallinckrodt Creating Two Companies: Generics And Innovative Specialty Drugs

The company, which makes generic opioid products and the controversial Acthar Gel, is looking to chart a new course for the future – or make that two new courses.

Business Strategies Companies

Asia Deal Watch: ReVance Licenses Chinese Rights To Botox Competitor To Fosun

With Phase III data in 2,800 patients for reducing frown lines, ReVance anticipates filing RT002 for US approval in 2019. ABL licenses two bispecific antibody candidates to TRIGR, while Sun looks to expand in dermatology with Pola buyout.

Deals Asia Pacific
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register